Biosimilar Monoclonal Antibodies

monoclonal antibody (mAb) is originally produced by a single B-cell. Biosimilars are a lot complicated than small-molecule medicine and generics. In the past few years, monoclonal antibody drugs have dominated the world's largest biopharmaceutical drug sales, and in the coming years, monoclonal antibody drugs will continue to be the main force. Considering the huge profit margins and potential market, the monoclonal antibody-based therapeutics is the hot territory many pharmaceutical companies chases. This session will summarize the market in terms of therapeutic applications, type, and structure of mAbs, dominant companies, manufacturing locations, and emerging markets. These requirements would lead to greater development in the process and tighter quality controls during the production of biosimilar mAbs.

  • FDA-approved mAb drugs
  • Monoclonal antibody therapy
  • Anti-Cancer Antibodies
  • Cancer Immune therapy
  • Antibody Humanization Technologies
  • Biotherapeutics : Early Analytical Development

Related Conference of Biosimilar Monoclonal Antibodies

October 21-22, 2019

23rd European Biotechnology Congress

Zurich, Switzerland
November 26-27, 2019

International Conference On Genomics and Molecular Biology

Lisbon | Portugal
November 26-27, 2019

International Conference on Cell and Gene Therapy

| Lisbon, Portugal
February 24-25, 2020

24th Global Congress on Biotechnology

London, UK
March 16-17, 2020 |

12th World Congress and Expo on Cell & Stem Cell Research

Chicago, Illinois, USA

Biosimilar Monoclonal Antibodies Conference Speakers

Recommended Sessions

Related Journals

Are you interested in